Markets

Viatris Secures Japan Approval For WAKIX In Treating Excessive Daytime Sleepiness Linked To Sleep Apnea And Narcolepsy

Sep 16, 2026 · 07:01 AM ET· updated 1h ago

Approval Addresses High Unmet Medical Need and Further Advances Viatris' Innovative Portfolio in JapanPITTSBURGH, Sept. 16, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today

Why It Matters

Viatris got permission to sell a sleep medicine in Japan. This shows the company can reach new customers and grow its business.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

VTRS16.65

+0.00 (+0.01%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.